Overview
The CDSCO has given its first‑ever approval for a dengue vaccine in India – Qdenga. The vaccine is already licensed in more than 40 countries and has received WHO prequalification. India faces a heavy dengue burden, with expanding presence of the Aedes mosquito into semi‑urban and rural districts, making vector control harder.
Key Developments
- Approval of Qdenga for use without prior dengue‑infection screening.
- Two‑dose schedule spaced three months apart.
- Higher efficacy against DENV‑2 and DENV‑1; limited data for DENV‑3 and DENV‑4 in seronegative individuals.
- Potential pricing challenge due to Takeda’s tiered‑pricing model.
- Operational challenge of delivering the second dose to mobile migrant workers.
Important Facts
Four dengue serotypes (DENV‑1 to DENV‑4) circulate in India. Protection against each serotype is essential because a second infection with a different serotype can trigger antibody‑dependent enhancement, leading to severe disease. The earlier vaccine Dengvaxia required pre‑screening for prior infection, a restriction that Qdenga avoids.
Clinical data show the first dose offers uneven protection: strong against DENV‑1 and DENV‑2, weaker for DENV‑3 and DENV‑4. The TIDES trial flagged a possible negative efficacy for hospitalisation due to DENV‑3 among seronegative children.
While DENV‑2 remains the dominant serotype, DENV‑3 cases are rising. If DENV‑3 dominates the 2026 monsoon season, the vaccine’s impact could be lower, especially for those receiving only the first dose before exposure.
Exam Relevance
Understanding Qdenga’s approval touches on several UPSC syllabus areas:
- Health governance: Role of CDSCO in drug approval and post‑marketing surveillance.
- Vector‑borne diseases: Epidemiology of dengue, vector control challenges, and the impact of urbanisation.
- Vaccine policy: Pricing strategies, equity in access, and the need for negotiation with manufacturers.
- International health regulations: Importance of WHO prequalification for global acceptance.
Way Forward
To maximise public‑health benefits, the government should:
- Negotiate a lower price under Takeda’s tiered‑pricing model to ensure affordability for urban slum dwellers.
- Strengthen cold‑chain and outreach mechanisms to guarantee the second dose reaches migrant and hard‑to‑reach populations.
- Enhance surveillance for serotype shifts, especially monitoring DENV‑3 trends during the monsoon.
- Consider supplementary vector‑control measures in semi‑urban and rural districts where Aedes mosquitoes are expanding.
- Educate the public about the two‑dose schedule and the importance of completing it, even for those without prior dengue exposure.
Effective rollout of Qdenga will require coordinated action across health ministries, state governments, and community organisations. Vigilance, affordable pricing, and robust delivery mechanisms are essential to prevent complacency and to curb dengue’s growing threat.